Manan Shah

Assistant Professor, (GU/Melanoma) @RushCancer| Chief Fellow @OSUCCC_James | Internal Medicine @MSMEDU | Associate Editor @TheMedNet| Immunotherapy outcomes

[Karine Tawagi MD @DrKarineTawagi]

Another GU FDA approval June 12, 2026:

Capivasertib + Abi/Pred in mCSPC, based on ➕rPFS (HR 0.81)

⚠️ OS immature
⚠️ cost/toxicity: diarrhea, ⬆️BG, rash

❓How does it compare to triplet w/ docetaxel
❓biomarker refinement: IHC cutoff 90% vs NGS PTEN-loss VS p-AKT
❓duration

[Pavlos Msaouel @PavlosMsaouel]

Cracked ctDNA in #kidneycancer, showed relative contribution with KIM-1 *and* harnessed prognostic information to guide patient care in oligometastatic disease via K-COMPASS 👉 https://t.co/DnlfqzoXVJ 🔬

[Yüksel Ürün @DrYukselUrun]

FDA approved capivasertib + abiraterone/prednisone for PTEN-deficient metastatic prostate cancer.
Grateful to have been one of the investigators in CAPItello-281.
@US_FDA @APCCC_Lugano @OncoAlert @ONCOassist @OpenMedicineHQ @AnkaraUni
https://t.co/fJsf0XB5oe

[Manan Shah @1588man]

We're hiring a GU Medical Oncologist!

Join the growing GU oncology program @RushMedical and help shape the future of cancer care, research, and education.@RushCancer @HemOncFellows @hemeoncfellow @urotoday #GU Oncology
https://t.co/QoVosLSxMc

[Katy Beckermann @katy_beckermann]

Not many prostate bispecifics in the oral sessions at ASCO this year. Most of the activity was in the posters.

Four programs, four targets:
🔬 STEAP1 × CD3, xaluritamig + abiraterone (Sumey, 5070): the only one with efficacy data. PSA50 65%, RECIST ORR 57% in taxane-naïve mCRPC. Inphase 3 XALience.
🔬 KLK2 × CD3, pasritamig + docetaxel (PASenger, TPS5139): already in randomized phase 3, n=800, rPFS primary.
🔬 DLL3 × CD3, tarlatamab (TIDAL, TPS5142): phase 2 in DLL3-positive neuroendocrine prostate, a setting with few options.
🔬 VEGF × PD-1, ivonescimab (NCT06567314): not a T-cell engager, testing the microenvironment in mCRPC.

The targets are diversifying (STEAP1, KLK2, and DLL3 each handle prostate specificity differently), and the trials are moving earlier rather than sitting late salvage.

Excited to follow this movement and the idea of an immune based therapy in this typically immune resistant tumor.

#ProstateCA #mCRPC #GUonc #ASCO26 @OncoAlert

[UroToday.com @urotoday]

MEVPRO-3 trial: Enzalutamide with or without mevrometostat in metastatic hormone-sensitive #ProstateCancer. @neerajaiims @huntsmancancer joins @l_ballas @CedarsSinai to discuss the MEVPRO-3 trial design which enrolls 1,000 patients with newly diagnosed #mHSPC randomized to ADT + enzalutamide vs ADT + enzalutamide + mevrometostat. #WatchNow > https://t.co/9rvt7FPUpN

[Javier Puente @docjavip]

#ASCO26 Panitumumab showed remarkable activity in SMARCB1-deficient renal medullary carcinoma, achieving an ORR of 54% with 15% CR in heavily pretreated patients. These data support wild-type EGFR as a promising therapeutic target in one of the most aggressive kidney cancers

[UroToday.com @urotoday]

Darolutamide alone for nonmetastatic #CSPC: 52-week safety and efficacy results from the #ARAMON trial. @alaccetti @nyulangone joins @TDorffOnc @cityofhope to discuss the 52-week results from ARAMON, a phase 2 study of darolutamide monotherapy in biochemically recurrent and low-volume metastatic prostate cancer. #WatchNow > https://t.co/ZrUKkNV2s5

[Toni Choueiri, MD @DrChoueiri]

Congrats to Dr Taplin, all @DanaFarber_GU @DanaFarber and #PROTEUS team on a new frontier in high-risk prostate cancer.

Now officially in @NEJM !

https://t.co/36dUY9OUBN

[RUSH Heme/Onc @RushHemOnc]

Rush Hem/Onc fellows at 2026 ASCO annual meeting ~ Come to visit @RushCancer Booth #11019

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Ab#4515 @ASCO #ASCO26 by @emanuele_crupi👉 https://t.co/nAA0Rgbb30👉Ph2 study of gemcitabine, 5-FU, and cisplatin (GemFLP) in advanced urinary tract adenoCa#bladdercancer👉44% ORR w/ durable response & baseline CA125 was associated w/ OS👇@OncoAlert @urotoday @bladdercancerUS

[Manan Shah @1588man]

What started as a concept to enhance advanced training MedEd is now presented at #ASCO26🎉. Catch our poster on 6/1. Excited for learning and reconnecting with friends and mentors. #MedEd need of the hour @OSUhemoncfellow @RushHemOnc @Sonia_lite https://t.co/9Ogou9UHnJ

[Toni Choueiri, MD @DrChoueiri]

#DrJunruChen presents first-line cadonilimab + axitinib in advanced non-clear cell RCC, encouraging early signal in a tough, heterogeneous space. ORR 51.4%; DCR 97.2%. #ASCO26 #RCC

#ASCO26 #RCC
@OncoAlert @ASCO @OncBrothers

[Karine Tawagi MD @DrKarineTawagi]

First in class PD1/CTLA4 bispecific ph1 in nccRCC #ASCO26

➡️37 pts, ORR 51.6% esp in liver mets, mPFS 16.7 mo

⛔️ heterogeneity & high FH def population, no DLTs

✅promising 1L and manageable safety, not ready for clinic, but reinforces IO/TKI in nccRCC, driven by FH-def

[Cristiane D Bergerot, PhD, FASCO @crisbergerot]

One to watch at #ASCO26: TALAPRO-3, a Late-Breaking Oral Abstract evaluating talazoparib + enzalutamide in HRR-altered metastatic castration-sensitive prostate cancer @neerajaiims @ASCO

https://t.co/ByNa4SiPOU

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Ab#4507 @ASCO #ASCO26 by @tompowles1 @shilpaonc👉https://t.co/fxlybBjl6j👉3.5 yr f/u of Ph3 EV-302 in aUC #bladdercancer👉42-month OS rate, 44% vs 24.6%; HR=0.53👉among pts w/ CR, 66% had initially PR👇 @OncoAlert @urotoday @uromigos @BladderCancerUS

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Ab#4502 @ASCO #ASCO26 by @DrChoueiri👉 https://t.co/SZg3hfw1wU👉ctDNA analysis from KEYNOTE-564 trial #kidneycancer👉ctDNA+ associated w/ worse DFS👉ctDNA clearance was higher in pembro arm👇@tompowles1 @OncoAlert @urotoday @kidneyCAN

[Karine Tawagi MD @DrKarineTawagi]

GU schedule by day 📆 for #ASCO26 & (among others) looking forward to 💫

1) Bladder CA:
-Data on novel nectin-4 ADCs: #NEXUS01, #EXCEED + #DURAVELO2, Bulumtatug, SHR-A2102
-Updates for: #EV302, #KN905 QoL
-RAD-IO TMT w/ durva 
-GemFLP in bladder adenoCA

[Cristiane D Bergerot, PhD, FASCO @crisbergerot]

Honored to be part of this @sitcancer guideline on IO for #KidneyCancer

This work offers evidence- & consensus-based recommendations for adjuvant & metastatic RCC, special populations, response monitoring, & patient education/QOL @DrRanaMcKay @montypal

https://t.co/HkwhHm3Brm

[Cristiane D Bergerot, PhD, FASCO @crisbergerot]

Cabazitaxel shows consistent real-world effectiveness in mCRPC, regardless of line of therapy @JCOOA_ASCO @Micah_Ostrowski @neerajaiims @umangtalking

In 1,315 patients:
🔵rwTTNT: 4.7 months
🔵rwOS: 8.6 months

https://t.co/9z0TuvPrnD